Abstract

Objective: Pancreatic cancer-related mortality is increasing worldwide, and prevention methods and effective novel therapies are required. In pancreatic cancer, sodium-glucose cotransporters (SGLT) are involved in glucose uptake. This study aimed to clarify the association between SGLT2 inhibitors and pancreatic cancer development.
Materials and methods: A nested case-control study was conducted using the JMDC administrative claims database (January 2005 to June 2020). Patients newly diagnosed with type 2 diabetes mellitus (T2DM) were included, and cases were defined as patients who developed pancreatic cancer. Patients with outcomes were randomly matched to a maximum of 20 controls according to age (± 5 years), sex, and calendar date (month and year) of the first T2DM diagnosis through risk set sampling.
Results: Of the 181,107 T2DM patients, 363 cases and 7,043 controls were selected with 14 and 457 patients prescribed SGLT2 inhibitors, respectively. Cumulative administration of SGLT2 inhibitors for > 180 days was significantly inversely associated with the development of pancreatic cancer (adjusted odds ratio: 0.58, 95% confidence interval: 0.31 – 0.99).
Conclusion: SGLT2 inhibitors may reduce the risk of developing pancreatic cancer in T2DM patients. The number of patients over 65 years of age was small in this study due to the nature of the data source. Further studies with larger sample sizes including older patients are needed.

Author Details

Authors

• Yuki Tanaka
• Satoshi Yokoyama
• Chihiro Nakagawa
• Takaya Uno
• Kouichi Hosomi

Departments

• Division of Drug Informatics, School of Pharmacy, Kindai University, Higashiosaka City, Osaka, Japan

Address

Satoshi Yokoyama, PhD
Division of Drug Informatics, School of Pharmacy
Kindai University
3-4-1 Kowakae, Higashi-Osaka,
Osaka, 577-8502, Japan
Email: [email protected]

Log in for Subscribers

Citation